Autophagy in Plasma Cell Ontogeny and Malignancy by unknown
Autophagy in Plasma Cell Ontogeny and Malignancy
Enrico Milan1,2 & Monica Fabbri1,2 & Simone Cenci1,2
Received: 23 February 2016 /Accepted: 25 February 2016 /Published online: 16 March 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Autophagy is a highly conserved pathway that re-
cycles cytosolic material and organelles via lysosomal degra-
dation. Once simplistically viewed as a non-selective survival
strategy in dire straits, autophagy has emerged as a tightly
regulated process ensuring organelle function, proteome plas-
ticity, cell differentiation and tissue homeostasis, with key
roles in physiology and disease. Selective target recognition,
mediated by specific adapter proteins, enables autophagy to
orchestrate highly specialized functions in innate and adaptive
immunity. Among them, the shaping of plasma cells for sus-
tainable antibody production through a negative control on
their differentiation program. Moreover, memory B cells and
long-lived plasma cells require autophagy to exist. Further, the
plasma cell malignancy, multiple myeloma deploys abundant
autophagy, essential for homeostasis, survival and drug
resistance.
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Introduction
Plasma cells (PCs) are terminal immune effectors of the B
lymphocyte lineage devoted to massive immunoglobulin
(Ig) synthesis and secretion. Their differentiation entails pro-
found genetic reprogramming and cellular reshaping, and im-
poses intense stress, counterbalanced by ad hoc adaptive strat-
egies. Macroautophagy (conventionally referred to as
autophagy) is a conserved intracellular membrane trafficking
process that engulfs unwanted supra-molecular entities and
directs them to lysosomes for degradation and recycling. In
addition to its prime metabolic role maintaining energy ho-
meostasis, autophagy evolved diverse complex functions, in-
cluding proteome and organelle quality control, cell differen-
tiation and stress responses. Recently, a variety of regulatory
functions across innate and adaptive immunity have been rec-
ognized, including intracellular microbe clearance, inflamma-
tion, lymphocyte development and antigen presentation. We
disclosed a previously unrecognized role moderating PC
differentiation and function, whereby autophagy sustains both
short- and long-term humoral immunity. Moreover, multiple
myeloma cells proved exquisitely dependent on autophagy.
This essay recapitulates and discusses these findings and their
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pathophysiologic and therapeutic implications in the context
of immunity and cancer.
Autophagy and Autophagic Receptors
Autophagy is a highly conserved intracellular self-digestive
pathway that consists in the sequestration of substrates in
sho r t - l i v ed doub l e -membrane ve s i c l e s , c a l l ed
autophagosomes, subsequently delivered to the lysosome (in
animal cells) or the vacuole (in yeast and plant cells) for con-
tent degradation and recycling. The prime conserved function
of autophagy is to sustain cellular metabolism in conditions of
nutrient starvation. However, crucial roles have emerged in a
wide variety of biological processes such as cell differentia-
tion and death, immunity, and aging. Indeed, the notion of
autophagy as a non-selective bulk cytoplasmic degradation
pathway triggered by starvation has been challenged and
revisited in view of its established capacity to ensure selective
elimination of harmful aggregates (aggrephagy) and microor-
ganisms (xenophagy), as well as homeostatic organelle renew-
al through dismantlement of mitochondria (mitophagy), ribo-
somes (ribophagy), endoplasmic reticulum (ER-phagy),
peroxysomes (pexophagy), and lipid droplets (lipophagy)
(reviewed in [1]).
Autophagic selectivity is conferred by dedicated receptor/
adapter proteins that recognize the substrate and mediate its
engulfment into autophagosomes. Autophagy receptors share
three key moieties: (i) a ubiquitin (Ub)-binding domain for
target recognition; (ii) an LC3-interacting region cross-
linking the substrate with the autophagic machinery; (iii) a
PB1 domain for polymerization [2]. The degradation signal,
ubiquitination, is shared with the Ub proteasome system
(UPS); however, while K48-linked poly-Ub chains are
recognized by proteasomes, K63-linked Ub chains are prefer-
entially targeted by autophagy [3].
The prototypical autophagic receptor, SQSTM1/p62, has
been implicated in many types of selective autophagy. Other
receptors include NBR1, optineurin, NDP52 and TAX1BP1
[2]. In addition to the domains required for autophagic activ-
ity, p62 harbors multiple signaling moieties, including a ZZ-
type zinc finger domain, two nuclear localization signals
(NLS), a nuclear export signal (NES), and a KEAP1
interacting region (KIR) [2]. As a result, p62 contributes to
shape a number of signaling pathways, including Nrf2, NF-
kB, and mTOR [4]. Nrf2 mediates a critical cellular defense
against oxidative damage. P62 promotes Nrf2 activity via its
inhibitory interaction with KEAP1, a redox-sensitive substrate
adapter for a Ub-ligase complex. In unstressed conditions,
KEAP1 drives constant ubiquitination and proteasomal deg-
radation of Nrf2. Under stresses that result in accumulation of
p62, its increased binding with KEAP1 liberates and activates
Nrf2 [5, 6], linking protein and redox homeostasis. P62 has
also been shown to modulate programmed cell death. For
instance, p62 participates in the full activation of caspase 8
during ligand-induced apoptosis [7]. Thus, p62 is a hub sig-
naling adapter integrating diverse stimuli to coordinate protein
homeostasis with different cell and tissue functions. Glucose,
lipid and skeletal metabolism depend on p62 [5, 6, 8, 9], as
mice lacking p62 display mature-onset insulin resistance and
obesity [8]. In neurodegenerative disorders, p62 bound to Ub-
proteins is commonly found in diagnostic inclusion bodies,
such as Lewy bodies, huntingtin aggregates and neurofibril-
lary tangles, respectively in Parkinson’s, Huntington’s and
Alzheimer’s diseases [10]. P62 mutations, generally mapping
to the Ub-binding domain, are associated with altered NF-κB
mediated osteoclastogenesis in Paget’s disease of bone, an
age-onset chronic skeletal disorder characterized by focal en-
hanced bone turnover [11]. In line with the complex integra-
tive functions of p62 alluded to above, it is not surprising that,
although highly conserved in metazoans, p62 is absent in
plants and fungi [1].
Immune Functions of Autophagy
Autophagy orchestrates many innate and adaptive immune
functions, including elimination of microorganism, control
of inflammation, secretion of immune mediators, antigen pre-
sentation, and lymphocyte development [12, 13].
Clearance of invading microbes through autophagy
(xenophagy, i.e. eating the stranger) appears the most primor-
dial immune response against intracellular pathogens.
Invading microorganisms trigger autophagy via starvation in-
duced by nutrient competition, or through receptors such as
toll-like receptors [14]. Infected cells then activate LC3-
associated phagocytosis (LAP), which in turn drives
phagosome-lysosome fusion and subsequent degradation of
invading bacteria [15]. Autophagy receptors can initiate
xenophagy by recognizing specific modifications of cytosolic
bacteria, such as ubiquitination, binding to galectin, or
pathogen-associated lipid changes [1, 16]. Many mechanisms
evolved to circumvent eukaryotic control, witnessing the rel-
evance of autophagy against bacteria [12]. Autophagy also
mediates viral recognition and destruction. For example, cap-
sid proteins of the neurotropic Sindbis virus are degraded via
p62-dependent autophagy [17]. Thus, SQSTM1/p62-like re-
ceptors (SLRs) have been proposed to constitute a new family
of innate pattern recognition receptors [12, 13].
Autophagy also regulates the inflammatory response by
modulating the activity of inflammasomes, cytosolic signaling
complexes that promote proteolytic processing and secretion
of the pro-inflammatory cytokines IL-1β and IL-18 [12].
These are leaderless proteins secreted through a non-
conventional and not fully elucidated process requiring the
autophagic machinery [18]. The autophagic control of
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inflammation is variegated. While in basal conditions autoph-
agy prevents inflammation by limiting mitochondrial produc-
tion of reactive oxygen species (ROS) and clearing pro-
inflammatory protein aggregates [19], upon exposure to
damage- or pathogen-associated molecular patterns (DAMPs
or PAMPs), autophagymediates secretion of IL-1β, IL-18 and
HMGB1, critical for the prompt establishment of a multicel-
lular inflammatory response [18]. At the same time, autopha-
gy limits excess inflammation by degrading inflammasomes
and pro-IL-1β [20].
Autophagy plays important functions also in adaptive im-
munity. One exemplar role is the regulation of lymphocyte
ontogenesis. Critical to T lymphocyte homeostasis, autophagy
sustains T cell survival upon TCR activation, and participates
in the selection of the T cell repertoire and in T cell maturation
[21, 22]. Autophagic clearance of damaged mitochondria is
essential in hematopoietic stem cells and for post-thymic T
cell maturation [22, 23]. Indeed, the maintenance of normal
numbers of CD4+ and CD8+ T cells requires functional Atg
proteins [24]. In activated T cells, autophagy sustains ATP
levels, controls proliferation and cytokine release [25].
Autophagy may also be involved in Th polarization, as sug-
gested by a model of M. tubercolosis infection, where lung
autophagy-deficient myeloid cells secreted higher amounts of
IL-17 [24, 26].
In the B lymphocyte lineage, autophagy influences transi-
tion of pro- to pre-B cells. Moreover, mice lacking the essen-
tial autophagy gene Atg5 in mature B cells show fewer B-1a
cells in the periphery [27, 28].
A large number of studies have linked autophagy to MHC
class I and class II antigen presentation [29–31]. In particular,
autophagy increases presentation and citrullination of exoge-
nous viral components and cytoplasmic self-antigens, contrib-
uting to the elimination of self-reactive T cells during thymic
maturation. Moreover, LAP directs exogenous antigens into
the antigen processing compartment [21]. Autophagy also
mediates cross-presentation of phagocytosed antigens on
MHC class I to prime CD8+ T cells in vivo [29–31], and
may influence MHC class I presentation by competing with
the proteasome for substrates [32]. However, autophagy is not
a universal antigen-presenting pathway, being, for example,
dispensable for presentation by B cells to cognate Tcells in the
germinal center [28].
Autophagy in Plasma Cell Ontogeny
PCs, terminal effectors of the B lymphocyte lineage special-
ized in large-scale antibody secretion, constitute the humoral
arm of adaptive immunity. Upon antigen encounter, B cells get
activated and start a complex program in secondary lymphoid
organs culminating in PC differentiation.Most antibody secret-
ing cells (ASCs) are short-lived and die within few days,
providing immediate defense against invadingmicroorganisms
[33]. During T cell-dependent immune responses, activated
follicular B cells in spleen and lymph nodes undergo affinity
maturation and class switch recombination in germinal centers,
which generate memory B cells and long-lived plasmablasts
endowed with the capacity to populate specific bone marrow
(BM) niches, where resident long lived PCs yield long-lasting
serological memory of the pathogen [34, 35].
PC differentiat ion involves a complex genetic
reprogramming network aimed to silence B cell identity and
to acquire the distinctive Ig-secretory phenotype, entailing
expression of the transcription regulators Blimp-1, IRF4 and
XBP1 [36]. Encoded by the Prdm1 gene, Blimp-1 represses
the specific B cell identity transcription factors Pax5 and Bcl-6
[37]. Recent work established that while IRF4 expression is
necessary for PC differentiation, Blimp-1 is specifically re-
quired for antibody production, but dispensable once ASCs
are formed [38]. Moreover, comprehensive gene target assess-
ment revealed that Blimp-1 is not only a repressor of B cell
identity genes involved in antigen presentation and class
switch recombination (including Aicda, which encodes the
cytidine deaminase AID), but also a transcriptional activator.
Indeed, Blimp-1 promotes Ig transcription and the conversion
from the membrane-bound to the secreted form of the Ig
heavy chain [39]. Moreover, Blimp-1 induces XBP1, a key
transcription factor of the unfolded protein response (UPR)
integral to PC differentiation [40, 41].
We have recently established a pivotal role of autophagy in
PC ontogeny. Having found concertedly increased expression
of autophagy related genes in differentiating PCs ex vivo, and
remarkable autophagic activity in both short- and long-lived
PCs in vivo, we then investigated PC ontogenesis in mice in
which autophagy is selectively ablated in B cells (Atg5f/f
CD19-Cre mice) [28]. Attesting to a developmental key role
for autophagy in PC differentiation, Atg5f/f CD19-Cre mice
showed reduced IgM and IgG responses following both T-
independent and T-dependent immunizations. Notably, al-
though long-lived PCs were normally represented in the BM
of Atg5f/f CD19-Cre mice, genomic characterization found no
recombined floxed Atg5 in long-lived PCs, revealing efficient
Darwinian selection for autophagy-proficient PCs, which
demonstrated the absolute requirement for autophagy in BM
PCs. Moreover, Atg5f/f CD19-Cremice had a profound defect
of antigen-specific long-lived PCs. Thus, autophagy is essen-
tial for PC maintenance in the BM and serological memory
[28]. An independent confirmation came from a recent work
that identified and characterized human BM PCs from a gene
expression and functional standpoint. Here, the CD19−
CD38hi CD138+ population defined a subset of very long-
lived PCs that showed abundant autophagy and distinctive
high expression of autophagic genes [42].
To understand why PCs require autophagy, we devised an
unbiased comparative proteomic analysis of wild-type and
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Atg5−/− differentiating PCs by stable isotope labeling by amino
acids in cell culture (SILAC). The proteome of developing PCs
could be entirely labeled in as little as 3 days, not only enabling
this approach, but also demonstrating the unique degree of
proteome plasticity associatedwith this cellular metamorphosis.
Proteome analysis revealed more abundant ER in Atg5−/− PCs,
further confirmed by qualitative and quantitative electron
microscopy techniques, disclosing selective ER-phagy in
differentiating PCs. Autophagy-deficient PCs also showed
higher expression of the master regulators Blimp-1 and
XBP1, and higher Ig expression, manufacturing and secretion
[28]. As a result, Atg5−/− PCs ran short of ATP and died pre-
maturely, explaining the requirement of autophagy for normal
antibody responses in vivo [28]. This study has several
implications. First, it discloses a new autophagy-dependent
mechanism regulating PC differentiation. Puzzlingly,
autophagy was shown not to mediate the disposal of Ig
byproducts. Hence, a direct link between ER size and
enhanced XBP1 signaling is to be excluded, and the mecha-
nism whereby autophagy contains Blimp-1 expression
remains elusive. Second, this work unveils a previously
unsuspected level of plasticity in PC biology and antibody
responses, whose functional significance in immune patho-
physiology awaits elucidation. The implication of autophagy
in human primary antibody deficiencies will shed light on this
issue [43]. Of note, further expanding its significance across
humoral immunity, autophagy recently proved essential also
for the survival of memory B cells [44]. The functions of
autophagy hitherto recognized in PC ontogeny are synoptically
summarized in Fig. 1.
Autophagy in Cancer
The role of autophagy in cancer is complex and multifaceted.
Autophagy is primarily a homeostatic process that recycles
damaged proteins and organelles, maintaining cellular homeo-
stasis, thereby preventing the accumulation of ROS, inflam-
mation, and oncogenic mutations [45]. In keeping with its
broad cytoprotective role, genetic defects of autophagy in
mice have been associated with higher susceptibility to meta-
bolic stress, genomic damage, and tumorigenesis, establishing
the notion that autophagy is oncosuppressive in normal cells
[46]. Monoallelic deletions of the gene encoding the essential
autophagic player beclin1 have been detected in 40 to 70 % of
human breast, prostate and ovarian cancers; however, the ge-
nomic position of beclin1 close to the established tumor sup-
pressor BRCA1 disputes the oncogenic mechanism of such
mutations [47]. In absence of autophagy, the inability to clear
p62+ aggregates has been shown to increase ROS levels, DNA
damage and cell death [48, 49]. Moreover, accumulation of
p62 has been proposed to be tumorigenic itself through altered
NF-kB and Nrf2 activity [50, 51].
On the other hand, autophagy deficiency in mouse liver
leads to the development of benign hepatomas, suggesting
that autophagy may be protective from neoplastic transforma-
tion, but is also involved in the acquisition of malignant fea-
tures, promoting cancer growth, survival and metastatization
[52]. This is in line with the general notion that transformed
cells experience more stress due to deregulated growth, hyp-
oxia, nutrient deprivation, and oxidative insults, and hence
rely more on adaptive strategies than normal cells.
Fig. 1 Functions of autophagy in normal and malignant plasma cells. In
differentiating plasma cells, autophagy restricts the ER and moderates
Blimp-1 expression, containing Ig production to sustainable levels,
ultimately supporting antibody responses [28]. B cell autophagy is
dispensable for the germinal center reaction [28], while the maintenance
of memory B cells and bone marrow long-lived plasma cells depend on
autophagy [28, 42, 44]. In multiple myeloma, the malignant counterpart
of memory plasma cells, autophagy is required for secretory and energetic
homeostasis and survival, and confers specific resistance to the first-in-
class proteasome inhibitor, bortezomib [56]. The functions of autophagy
hitherto recognized across plasma cell ontogenesis are summarized in
grey boxes
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Autophagy may thus be essential for cancer cells to resist
metabolic and environmental stress. Indeed, many cancer
types show higher autophagic activity than normal counter-
parts. Moreover, certain tumors may be particularly depen-
dent on autophagy for mitochondrial homeostasis due to
peculiar metabolic features, such as impaired acetyl-CoA
biosynthesis in RAS-driven cancers. Of therapeutic inter-
est, autophagy is often upregulated by chemotherapy, offer-
ing putative targets to overcome primary and secondary
drug resistance [45].
Autophagy in Multiple Myeloma
Multiple myeloma (MM), the malignant counterpart of BM
long-lived PCs, is a frequent and incurable tumor account-
ing for ~2 % of all cancer deaths. MM biology is a unique
model to study the role of autophagy in cancer. Intense Ig
production is associated with high workload for the UPS; as
a result, MM is exquisitely vulnerable to proteasome inhib-
itors (PIs), but resistance inevitably ensues [53]. Autophagy
has been shown to cooperate with the UPS in animal and
cellular models of proteotoxicity [54, 55], offering an at-
tractive target to overcome PI resistance. This rationale,
together with the essential role of autophagy identified in
normal PCs [28], encouraged us to investigate the constitu-
tive function and relevance of autophagy in MM. We found
that myeloma cells display remarkable basal autophagic
activity as compared to other tumors, including B lympho-
mas, and that autophagy is necessary for MM cell survival
[56]. Wide-scope and hypothesis-driven approaches re-
vealed two main autophagic tasks in myeloma cells: con-
tainment of the secretory apparatus, as observed in normal
PCs (vide supra), and tight cooperation with the UPS for
the clearance of ubiquitinated proteins through a p62-
dependent autophagic reserve [56] (Fig. 1). Notably, in my-
eloma cells, autophagy participates in Ub-protein clearance
in basal conditions (i.e. in absence of PIs). Despite this
close collaboration, combined inhibition of autophagy and
the UPS in preclinical studies yielded discrepant results,
ranging from synergy to antagonism [56–58]. Adding to
complexity, deregulated autophagy has been shown to pro-
mote MM cell death, through a non-apoptotic caspase 10-
dependent mechanism [59]. Such complexity is likely
accounted for by the multiple, integrated functions con-
trolled by autophagy. Hence, dissecting tissue- and
cancer-specific tasks, substrates and molecular mechanisms
of autophagy is needed to design new targeted therapeutic
strategies.
Our study identified p62 as a novel, specific anti-myeloma
target [56]. We found that the genetic ablation of p62 induced
massive and rapid death of myeloma cells, but not B lympho-
mas. Moreover, p62 yielded specific PI resistance by
mediating a twofold plastic adaptive response to proteasome
stress. First, PIs rapidly induced de novo expression of p62,
but not other autophagy receptors. Second, PIs dramatically
modified the interactome of p62, inducing its rapid nucleation
onto detergent-insoluble aggregates, at the expense of numer-
ous signaling interactors, as revealed by fluorescent micros-
copy and quantitative proteomics [56]. Hence, under PIs, MM
cells intensify p62-dependent autophagic degradation so as to
compensate for proteasome insufficiency, but do so by
neglecting other cytoprotective functions. Thus, understand-
ing which integrative role of p62 is crucial for myeloma via-
bility holds promise to disclose new therapeutic targets. Of
interest, we found that p62-silenced myeloma cells rapidly
lose intracellular ATP prior to cell death, in keeping with a
role of p62 in mitochondrial homeostasis [56]. One possible
mechanism is the maintenance of mitochondrial health via
mitophagy, whose mechanisms are still debated. A paradig-
matic pathway involves the proteins PINK and Parkin. The
former is a short-lived kinase that localizes to mitochondria.
Upon mitochondrial depolarization, PINK is stabilized and
recruits the cytosolic ubiquitin-ligase Parkin to ubiquitinate
proteins on the outer mitochondrial membrane, marking dam-
aged mitochondria for elimination. The autophagic receptors
involved are under investigation, with a recent work implicat-
ing NDP52 and optineurin, and not p62, in PINK-mediated
mitophagy [60]. In fact, the homeostatic and integrative func-
tions linking autophagy and mitochondria may extend beyond
mitophagy, as witnessed by the intense relationship between
p62 and the mitochondrial network [56].
Conclusions and Perspectives
Autophagy is a tightly regulated intracellular recycling pro-
cess underlying organelle quality control, proteome plastic-
ity, cell differentiation and stress responses, with essential
roles in health and disease. Selective target recognition by
specific adapter proteins enables autophagy to orchestrate
highly specialized tissue-specific tasks, including functions
in innate and adaptive immunity. The recently identified
negative control exerted by autophagy on the Blimp-1-
dependent differentiation program shapes PCs for sustain-
able antibody production. This control discloses a previous-
ly unsuspected level of plasticity of PC biology, whose
mechanisms and pathophysiological significance in humor-
al immunity warrant investigation. On the malignant side,
in MM cells autophagy collaborates closely with the UPS
for protein homeostasis, providing a framework to over-
come PI resistance. Moreover, the exquisite dependence
of malignant PCs on the autophagy adapter and hub signal-
ing integrator p62 recommends that autophagy-regulated
complex integrative functions be dissected to design novel
targeted therapies against myeloma.
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